REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regenxbio (RGNX) Misses Q3 EPS by 22c, Revenues Beat
November 5, 2019 4:55 PM ESTRegenxbio (NASDAQ: RGNX) reported Q3 EPS of ($0.94), $0.22 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $9.74 million.
Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial clinical hold following FDA notification related to certain commercial, third-party surgical devices; matter is not related to RGX-314 gene therapy candidatePositive interim update from RGX-314 Phase I/IIa trial for wet AMD presented in October at... More